The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.
Age ≥ 18 years
Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.
Metastatic histologically or cytologically confirmed pancreatic ductal adenocarcinoma.
Have metastatic disease
Have had prior chemotherapy for pancreatic cancer or prior chemotherapy within 5 years of enrollment for other cancer diagnoses.
Has received radiotherapy for pancreatic cancer.
Are receiving or have received any investigational agent or used an investigational device within 28 days prior to Day 1 of treatment in this study.
Has undergone major surgery, other than diagnostic surgery (i.e. surgery done to obtain a biopsy for diagnosis or an aborted Whipple), within 28 days prior to Day 1 of treatment in this study.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lead sponsor
NextCure, Inc.
Collaborator
Lustgarten Foundation
Collaborator